The conversation discusses hair regrowth results after using finasteride, minoxidil, and dermarolling for four months. Users inquire about dosages and when results were first noticed.
Wearing a high-quality hair system for festivals is generally considered acceptable, with the main concern being potential damage if someone pulls on it. Baldness is respected in these scenes, but long hair is more fetishized, making hair systems appealing for those seeking hookups.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.
User noticed tiny black hairs on temples after using rosemary oil along with finasteride, minoxidil, and 0.5mm derma roller. They are curious if these hairs will become terminal.
Rosemary Oil may inhibit the activity of 5α-Reductase, potentially promoting hair growth. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.
The user is starting a hair loss treatment including topical finasteride/minoxidil, derma rolling, ketoconazole shampoo, vitamins, exercise, and quitting caffeine. They are seeking advice on derma roller needle size, potential side effects, and additional recommendations.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.
The user shared progress after one year of using Minoxidil, rosemary oil, and dermarolling for hair loss, noting fuller hair despite some scalp exposure. Another user inquired about the dermarolling process and frequency.
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
A user discusses using tazarotene to enhance minoxidil's effectiveness for hair regrowth, believing it will make a significant difference. Others caution about potential risks of retinoids accelerating hair loss in some individuals.
The conversation discusses using a TCA 35% chemical peel on the scalp to potentially improve hair growth by addressing fibrosis and enhancing the effectiveness of topical treatments. The user also mentions trying microneedling and other methods like topical metformin and dutasteride for hair regrowth.
User "cheekykevin" shared 15-week progress using minoxidil and dermarolling, with positive results. Others suggested using ketoconazole for dandruff side effect.
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
The conversation discusses the hair loss treatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.
The user has been using oral finasteride, topical minoxidil, and a dermaroller for hair regrowth, noticing most improvement between months 3 and 4. Other users commented on the positive results and shared their own treatment routines.
Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
The user experienced significant hair improvement after 15 months of treatment, using finasteride initially, then switching to dutasteride, and recently adding topical minoxidil. They credit their progress to dutasteride and support from Haircafe, a YouTuber.
A user is experiencing increased hair shedding after using castor oil and rosemary oil twice a week for two months. They are concerned whether this is normal or if the castor oil's thickness is causing hair loss.